bioAffinity Technologies is developing a sputum-based diagnostic test designed to characterize lung inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD). Presented at CHEST 2026, the research explores an approach that combines inflammatory cell profiling with protein and cytokine measurements to provide a more comprehensive picture of lung inflammation than blood biomarkers alone may offer. The test analyzes sputum samples collected by patients at home using flow cytometry, enzyme-linked immunosorbent assays (ELISA) and machine learning. Preliminary findings demonstrate the detection of inflammatory cell populations and biomarkers associated with specific biologic therapies for asthma. This approach may support more personalized treatment selection and longitudinal monitoring of lung inflammation. A commercial test is in development.